AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35028011 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab + Brivanib
Number of subjects: 188
Study 35028011 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (in a separate cohort)
Number of subjects: 188
Study 33416292 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 686
Study 33416292 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze
Number of subjects: 686
Study 35107670 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralyzed group (rocuronium administered to maintain post‐tetanic count at ≤ 5)
Number of subjects: 42
Study 35107670 — intervention group
Group type: COMPARATOR
Intervention: Non-paralyzed group (no rocuronium administered)
Number of subjects: 42
Study 35107670 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralyzed group
Number of subjects: 42
Study 35107670 — intervention group
Group type: COMPARATOR
Intervention: Non-paralyzed group
Number of subjects: 42
Study 34913844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir + lamivudine
Number of subjects: 1433
Study 34913844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir + tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 1433
Study 35689137 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based cognitive behavioral therapy (CBT) program
Number of subjects: 30
Study 35689137 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 30
Study 33341153 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-only delivery with 16 fortnightly sessions
Number of subjects: 1152
Study 33341153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed delivery combining 12 group sessions with four home visits
Number of subjects: 1152
Study 33341153 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 1152
Study 33341153 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-only delivery and mixed delivery
Number of subjects: 1152
Study 32660977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 566
Study 32660977 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 566
Study 32660977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) monotherapy
Number of subjects: 566
Study 32660977 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 566
Study 35294301 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Intervention (YI)
Number of subjects: 37
Study 35294301 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living Education (HLE)
Number of subjects: 37
Study 33393598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 0
Study 33393598 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0
Study 33393598 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study 32901072 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve massage
Number of subjects: 60
Study 32901072 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft shoulder massage
Number of subjects: 60
Study 32901072 — intervention group
Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 60
Study 35932230 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g intravenous amoxicillin‐clavulanic acid after the induction of anaesthesia
Number of subjects: 871
Study 35932230 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 871
Study 36458661 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of trimetazidine dihydrochloride (35 mg)
Number of subjects: 24
Study 36458661 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of trimetazidine dihydrochloride (35 mg)
Number of subjects: 24
Study 36217617 — intervention group
Group type: EXPERIMENTAL
Intervention: DME group (n=81)
Number of subjects: 81
Study 33256042 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (P+)
Number of subjects: 36
Study 33256042 — intervention group
Group type: EXPERIMENTAL
Intervention: Endophyte-infected tall fescue seed (E+)
Number of subjects: 36
Study 33256042 — intervention group
Group type: COMPARATOR
Intervention: Endophyte-free tall fescue seed (E-)
Number of subjects: 36
Study 36227928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition programme using positive deviance approach; conducted for three months.
Number of subjects: 0
Study 36227928 — intervention group
Group type: COMPARATOR
Intervention: Comparison group receiving educational materials and menus after data collection.
Number of subjects: 0
Study 34100838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Bone Scalpel (USBS)
Number of subjects: 66
Study 34100838 — intervention group
Group type: COMPARATOR
Intervention: Control group (osteotome)
Number of subjects: 66
Study 32217111 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) alone
Number of subjects: 40
Study 32217111 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation plus full-thickness endoscopic suturing (FTS-APC)
Number of subjects: 40
Study 32217111 — intervention group
Group type: COMPARATOR
Intervention: Both groups (APC and FTS-APC)
Number of subjects: 40
Study 35222091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan (SV) treatment administered ultra-early (2 hours post-PCI)
Number of subjects: 1942
Study 35222091 — intervention group
Group type: COMPARATOR
Intervention: Sacubitril valsartan (SV) treatment administered after 3–7 days post-PCI
Number of subjects: 1942
Study 35222091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan (SV) treatment
Number of subjects: 1942
Study 35401970 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements or iron-containing multiple micronutrient powders (MNPs)
Number of subjects: 3300
Study 35401970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3300
Study 32696982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing in pediatric patients
Number of subjects: 112
Study 32696982 — intervention group
Group type: COMPARATOR
Intervention: Patch testing in adult patients (control group)
Number of subjects: 112
Study 32696982 — intervention group
Group type: EXPERIMENTAL
Intervention: Common allergens in pediatric patients
Number of subjects: 112
Study 32696982 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reactions to cosmetic allergens in pediatric patients
Number of subjects: 112
Study 32498328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate diet with caloric restriction (500 calorie/day deficit)
Number of subjects: 21
Study 32498328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate diet without caloric restriction
Number of subjects: 21
Study 33739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on CT radiomics features and clinical variables
Number of subjects: 981
Study 33739635 — intervention group
Group type: COMPARATOR
Intervention: Machine learning model based on CT radiomics features alone
Number of subjects: 981
Study 33739635 — intervention group
Group type: COMPARATOR
Intervention: Machine learning model based on clinical variables alone
Number of subjects: 981
Study 33739635 — intervention group
Group type: COMPARATOR
Intervention: Machine learning model based on visual CT severity scores and clinical variables
Number of subjects: 981
Study 33739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on CT radiomics and clinical variables
Number of subjects: 981
Study 33731544 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg bid
Number of subjects: 225
Study 33731544 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg bid
Number of subjects: 225
Study 33045433 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D repletion
Number of subjects: 19
Study 33045433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 36255344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to Hegu, Shenmen, and Yintang acupoints for 11 minutes
Number of subjects: 80
Study 36255344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 34052074 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate (10 bpm increase)
Number of subjects: 512891
Study 34052074 — intervention group
Group type: COMPARATOR
Intervention: Top quintile of resting heart rate
Number of subjects: 512891
Study 32894818 — intervention group
Group type: EXPERIMENTAL
Intervention: Data re-entry for preoperative variables
Number of subjects: 936
Study 32894818 — intervention group
Group type: EXPERIMENTAL
Intervention: Data re-entry for intra-operative variables
Number of subjects: 936
Study 32894818 — intervention group
Group type: EXPERIMENTAL
Intervention: Data re-entry for postoperative variables
Number of subjects: 936
Study 32894818 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy of data
Number of subjects: 936
Study 32894818 — intervention group
Group type: EXPERIMENTAL
Intervention: Date of diagnosis accuracy
Number of subjects: 936
Study 32894818 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications data accuracy
Number of subjects: 936
Study 35508343 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 194
Study 35508343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 34817389 — intervention group
Group type: COMPARATOR
Intervention: High intensity official information (OI)
Number of subjects: 195
Study 34817389 — intervention group
Group type: COMPARATOR
Intervention: Accurate social information (SI)
Number of subjects: 195
Study 34817389 — intervention group
Group type: COMPARATOR
Intervention: Low intensity official information (OI)
Number of subjects: 195
Study 34817389 — intervention group
Group type: COMPARATOR
Intervention: Control intensity of official information (OI)
Number of subjects: 195
Study 34817389 — intervention group
Group type: COMPARATOR
Intervention: Inaccurate social information (SI)
Number of subjects: 195
Study 35988178 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline treatment
Number of subjects: 120
Study 34151582 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent activity breaks from sitting (FABS)
Number of subjects: 16
Study 34151582 — intervention group
Group type: COMPARATOR
Intervention: Control (habitual lifestyle)
Number of subjects: 16
Study 32101308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multidisciplinary team meetings)
Number of subjects: 1428
Study 32101308 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 1428
Study 35572354 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX for 5 mins
Number of subjects: 60
Study 35572354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera extract for 5 mins
Number of subjects: 60
Study 35572354 — intervention group
Group type: COMPARATOR
Intervention: No disinfectant solution (control group)
Number of subjects: 60
Study 35325164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (less strict GDM screening)
Number of subjects: 35528
Study 35325164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (less strict GDM screening)
Number of subjects: 35528
Study 35325164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol D (less strict GDM screening)
Number of subjects: 35528
Study 35325164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol E (less strict GDM screening)
Number of subjects: 35528
Study 35325164 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (IADPSG criteria, control group)
Number of subjects: 35528
Study 35175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 162
Study 35175352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 33682887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (5 mg/d) prednisolone
Number of subjects: 371
Study 33682887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 33248303 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with continuous femoral nerve block
Number of subjects: 200
Study 33248303 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 36096984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg orally once daily in 4-week cycles
Number of subjects: 350
Study 36096984 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily continuously
Number of subjects: 350
Study 33319949 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus-intercostal interfascial plane block (SIPB)
Number of subjects: 102
Study 33319949 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous morphine analgesia
Number of subjects: 102
Study 35180667 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromolar approach using a video intubating stylet
Number of subjects: 36
Study 35180667 — intervention group
Group type: COMPARATOR
Intervention: Standard midline approach
Number of subjects: 36
Study 34240275 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP group
Number of subjects: 88
Study 34240275 — intervention group
Group type: COMPARATOR
Intervention: No TAP group
Number of subjects: 88
Study 34240275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 35158426 — intervention group
Group type: COMPARATOR
Intervention: Satralizumab administered in combination with baseline immunosuppressants (SAkuraSky) or as monotherapy (SAkuraStar)
Number of subjects: 176
Study 33296519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (16-40 IU/day, twice daily)
Number of subjects: 26
Study 33296519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 33507856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (15 minutes at 2 mA over DLPFC)
Number of subjects: 25
Study 33507856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (15 minutes at 2 mA over DLPFC)
Number of subjects: 25
Study 33507856 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 25
Study 33744377 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0
Study 34311054 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessment reporting
Number of subjects: 215
Study 34311054 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing data statistical analysis
Number of subjects: 215
Study 34311054 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL or patient reported outcomes
Number of subjects: 215
Study 33208878 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (Eso) 40 mg/day
Number of subjects: 66
Study 33208878 — intervention group
Group type: COMPARATOR
Intervention: No Esomeprazole (Eso-N)
Number of subjects: 66
Study 35007912 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR
Number of subjects: 120
Study 35007912 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 33217050 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 1000 mg/day, n = 26
Number of subjects: 51
Study 33217050 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 25
Number of subjects: 51
Study 33577358 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + ADX
Number of subjects: 432
Study 33577358 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 + PBO
Number of subjects: 432
Study 32622784 — intervention group
Group type: EXPERIMENTAL
Intervention: GLE 400 mg + PIB 120 mg
Number of subjects: 48
Study 32622784 — intervention group
Group type: EXPERIMENTAL
Intervention: GLE 600 mg + PIB 240 mg
Number of subjects: 48
Study 32622784 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 48
Study 34311766 — intervention group
Group type: EXPERIMENTAL
Intervention: The TANDEM intervention (cognitive behavioural approach)
Number of subjects: 0
Study 34311766 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative process data
Number of subjects: 0
Study 34311766 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 0
Study 34311766 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalisation process theory (NPT)
Number of subjects: 0
Study 32795322 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy (RT) volumes including all surgically dissected areas, including the tumour bed and dissected neck.
Number of subjects: 90
Study 32795322 — intervention group
Group type: COMPARATOR
Intervention: Omission of radiation to the pN0 hemi-neck(s).
Number of subjects: 90
Study 35378312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary education level (TEL)
Number of subjects: 1082
Study 35378312 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary education level (SEL)
Number of subjects: 1082
Study 32299515 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices implementation in pancreatic cancer care (including (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents)
Number of subjects: 2142
Study 32299515 — intervention group
Group type: COMPARATOR
Intervention: Best practices implementation in pancreatic cancer care
Number of subjects: 2142
Study 34270843 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci robot-assisted axillary lymph node dissection (dVALND)
Number of subjects: 60
Study 34270843 — intervention group
Group type: COMPARATOR
Intervention: Conventional axillary lymph node dissection (ALND)
Number of subjects: 60
Study 32128615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (APR) 125 mg on day 1 and 80 mg on days 2-3
Number of subjects: 141
Study 32128615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg (OLN10) on days 1-4
Number of subjects: 141
Study 32128615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg (OLN5) on days 1-4
Number of subjects: 141
Study 32128615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 35773662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-sub-Tenon's anesthesia (ST group)
Number of subjects: 120
Study 35773662 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous retrobulbar anesthesia (RB group)
Number of subjects: 120
Study 33561253 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (600 mg/d) plus cholecalciferol (200 IU/d) supplementation
Number of subjects: 56
Study 33561253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32227368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with cognitive behavioral therapy for 1 year
Number of subjects: 93
Study 32227368 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cognitive behavioral therapy for 1 year
Number of subjects: 93
Study 35690500 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3772 (1-, 2-, or 5-µg dose per polysaccharide)
Number of subjects: 0
Study 35690500 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (13-valent conjugate vaccine)
Number of subjects: 0
Study 35690500 — intervention group
Group type: COMPARATOR
Intervention: PPSV23 (23-valent polysaccharide vaccine)
Number of subjects: 0
Study 33032450 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular unloading (using an Impella)
Number of subjects: 686
Study 33032450 — intervention group
Group type: COMPARATOR
Intervention: No left ventricular unloading
Number of subjects: 686
Study 33032450 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular unloading
Number of subjects: 686
Study 34541683 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) 0.3 ml
Number of subjects: 44
Study 34541683 — intervention group
Group type: COMPARATOR
Intervention: Control group (open palatal wound after FGG harvest)
Number of subjects: 44
Study 34541683 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 44
Study 35263746 — intervention group
Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 20
Study 35263746 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 20
Study 32702689 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand‐assisted laparoscopic donor nephrectomy (R‐HALDN)
Number of subjects: 270
Study 32702689 — intervention group
Group type: COMPARATOR
Intervention: Left hand‐assisted laparoscopic donor nephrectomy (L‐HALDN)
Number of subjects: 270
Study 35288086 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33732434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (56mg) administered twice a week for four consecutive weeks
Number of subjects: 120
Study 33732434 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice a week for four consecutive weeks
Number of subjects: 120
Study 32858573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium-warfarin sequential (NWS) therapy (1-month nadroparin calcium by subcutaneous injection followed by 5-month warfarin by oral administration)
Number of subjects: 64
Study 32858573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulation therapy)
Number of subjects: 64
Study 32858573 — intervention group
Group type: EXPERIMENTAL
Intervention: NWS anticoagulation therapy
Number of subjects: 64
Study 32858573 — intervention group
Group type: EXPERIMENTAL
Intervention: NWS therapy group
Number of subjects: 64
Study 35090535 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion (2% lidocaine) for 6–12 hours starting at the beginning of surgery
Number of subjects: 562
Study 35090535 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 6–12 hours starting at the beginning of surgery
Number of subjects: 562
Study 34258469 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTAL intervention (18-min video highlighting obesity health risks and treatment outcomes)
Number of subjects: 42
Study 34258469 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 36007302 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filter air cleaners
Number of subjects: 540
Study 36007302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no air cleaners)
Number of subjects: 540